Evidence map›Paper›PMID 42273913›Full record

ArticleNucleic acids research2026

A hybrid RNA-based reporter assay for robust quantification of cytidine deaminase activity.

Anna Ligasová, Martina Horejšová, David Friedecký, Eva Pokorná, Pavel Klener, Karel Koberna

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna LigasováInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic.ORCID 0000-0002-1564-3768
Martina HorejšováInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic.
David FriedeckýLaboratory of Inherited Metabolic Disorders, Department of Clinical Chemistry, University Hospital Olomouc, Zdravotníků 248/7, 779 00 Olomouc, Czech Republic.
Eva PokornáInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague 2, Czech Republic.
Pavel KlenerInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague 2, Czech Republic.
Karel KobernaInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic.

Funding

European UnionMinistry of Education, Youth and Sports of the Czech Republic CZ.02.01.01/00/22_008/0004644Ministry of Education, Youth and Sports of the Czech Republic LM2018133Ministry of Education, Youth and Sports of the Czech Republic LM2023033Ministry of Education, Youth and Sports of the Czech Republic LX22NPO5102Ministry of Health of the Czech Republic NU22-08-00148Technology Agency of the Czech Republic TN01000013
6 · The paper itself

Abstract

We developed a robust, hybrid RNA-based reporter assay for the quantification of cytidine deaminase (CDA) activity, overcoming limitations of current methods often compromised by interferences in crude biological samples. Our two-step method physically separates the enzymatic reaction in cell lysates from a highly specific detection step in a selected and validated CDA-deficient reporter cell line (143B cell line). This design confers exceptional robustness, eliminating the need for sample purification. In the first step, a cell lysate converts 5-fluorocytidine to 5-fluorouridine. After heat inactivation of lysate proteins, 5-fluorouridine is quantified by its incorporation into reporter cell RNA, yielding a highly specific fluorescent signal. The detection limit of a formed product in the assay achieves 2.7 µM. The assay shows good correlation with LC-MS data, and its adaptability to a multi-well plate format makes it an ideal and cost-effective tool for high-throughput screening. We further applied this assay to reveal that CDA-positive cells actively secrete 5-fluorouridine, providing quantitative evidence for a potential therapeutic bystander effect.

Indexed as

Cytidine DeaminaseEnzyme AssaysRNACell Line, TumorCytidineGenes, ReporterHumansUridine5-fluorouridineCytidineCytidine DeaminaseRNAUridine

Identifiers

PMID42273913
PMCPMC13254536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.